Mesa Laboratories, Inc. (MLAB)
NASDAQ: MLAB · Real-Time Price · USD
100.81
-0.23 (-0.23%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Mesa Laboratories Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 26.93 | 27.32 | 28.21 | 32.91 | 49.35 |
Cash & Short-Term Investments | 26.93 | 27.32 | 28.21 | 32.91 | 49.35 |
Cash Growth | -1.44% | -3.16% | -14.27% | -33.31% | -81.30% |
Accounts Receivable | 44.1 | 41.97 | 39.06 | 42.55 | 41.22 |
Inventory | 26.37 | 25.37 | 32.68 | 34.64 | 24.61 |
Other Current Assets | 8.87 | 8.03 | 9.41 | 8.87 | 9.14 |
Total Current Assets | 106.27 | 102.69 | 109.35 | 118.98 | 124.32 |
Net Property, Plant & Equipment | 30.61 | 32.33 | 31.77 | 28.15 | 28.62 |
Other Intangible Assets | 83.35 | 96.88 | 113.75 | 216.82 | 250.12 |
Goodwill | 186.86 | 181.76 | 180.1 | 286.44 | 291.17 |
Other Long-Term Assets | 20.66 | 19.7 | 11.83 | 1.08 | 13.15 |
Total Assets | 427.75 | 433.35 | 446.8 | 661.83 | 707.37 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 4.93 | 5.75 | 6.04 | 6.13 | 7.9 |
Accrued Expenses | 36.62 | 42.46 | 22.79 | 21.53 | 26.33 |
Current Portion of Long-Term Debt | 5.63 | 101.05 | - | - | - |
Unearned Revenue | 14.72 | 14.71 | 15.48 | 15.69 | 13.83 |
Total Current Liabilities | 61.9 | 163.96 | 44.31 | 43.36 | 48.06 |
Long-Term Debt | 145.86 | 76.9 | 221.7 | 183.27 | 218.37 |
Other Long-Term Liabilities | 33.75 | 32.65 | 35.39 | 41.72 | 47.15 |
Total Long-Term Liabilities | 179.6 | 109.56 | 257.09 | 224.99 | 265.51 |
Total Liabilities | 241.5 | 273.52 | 301.4 | 268.35 | 313.57 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 375.35 | 358.54 | 343.64 | 332.08 | 313.46 |
Accumulated Other Comprehensive Income | -3.36 | -9.78 | -14.76 | -12.8 | 3.67 |
Retained Earnings | -185.75 | -188.94 | -183.49 | 74.2 | 76.68 |
Shareholders' Equity | 186.25 | 159.83 | 145.39 | 393.48 | 393.8 |
Total Liabilities & Equity | 427.75 | 433.35 | 446.8 | 661.83 | 707.37 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 151.48 | 177.95 | 221.7 | 183.27 | 218.37 |
Net Cash (Debt) | -124.55 | -150.63 | -193.48 | -150.36 | -169.02 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -22.38 | -27.79 | -35.92 | -28.05 | -31.68 |
Book Value | 186.25 | 159.83 | 145.39 | 393.48 | 393.8 |
Book Value Per Share | 33.47 | 29.48 | 26.99 | 73.40 | 73.81 |
Tangible Book Value | -83.97 | -118.81 | -148.46 | -109.78 | -147.48 |
Tangible Book Value Per Share | -15.09 | -21.92 | -27.56 | -20.48 | -27.64 |